How Recent Data Impacts Pancreatic Cancer Management

Integrity CE

M. Pishvaian

ASCO® 2024 Insights: "The GIANT Trial (EA2186) - Gem & nab-Paclitaxe…

2024 ASCO® Annual Meeting Insights Hub

E. Dotan

ASCO GI 2023 Expert Panel Discussion: Practice-Changing Updates

ASCO GI 2023 Conference Coverage

N. Uboha, A. Turk, K. Spencer, M. Cecchini

Updates in Perioperative Therapy of Pancreatic Cancer

Horizon CME

P. Philip

ASCO GI 2023 Key Studies

ASCO GI 2023 Conference Coverage

R. Kim, R. Mehta

ASCO® 2023 Summary: "GI Expert Panel Discussion on Key Trials Includ…

Insights from 2023 ASCO® Annual Meeting

Y. Janjigian, S. Cytryn, S. Maron

Debates in Neoadjuvant Therapy in Resectable Pancreatic Cancer: Why …

Integrity CE

W. Burns

ASCO® 2024 Insights: "Summary of the PASS-01 Trial - 1L FOLFIRINOX v…

ecancer

J. Knox

ASCO® 2024 Insights: "Biomarker-Directed Treatment for Pancreatic Ad…

2024 ASCO® Annual Meeting Insights Hub

J. Knox

GI Oncology Year in Review: Precision Medicine Update in Metastatic …

Yale Cancer Center

J. Lacy

Perspectives on the Recent FDA Approval of NALIRIFOX in Frontline Me…

UCLA Health

Z. Wainberg

ASCO® 2024 Insights: "EXPEL-PANC - A Ph2 Study of BXCL701 + Pembro i…

2024 ASCO® Annual Meeting Insights Hub

B. Weinberg

GI Oncology Year in Review: Metastatic Pancreatic Cancer - NAPOLI-3 …

Yale Cancer Center

J. Lacy

Updates in Nonmetastatic Upper-GI Adenocarcinoma

Integrity CE

J. Hernandez

Updates on Pancreatic Cancer - 2023 ASCO® Direct Philadelphia

Total Health

D. Lin

Year in Review: Pancreatic Cancers

OncoAlert

M. Lewis

ESMO GI 2024 Insights: Role of Personalized Medicine in Pancreatic C…

Insights from 2024 ESMO GI Annual Meeting

T. Seufferlein

FDA Approval of Liposomal Irinotecan/NALIRIFOX in 1L Metastatic Panc…

Shubham Pant

Pancreatic Cancer Updates From Yale Cancer Center

Yale Cancer Center

J. Lacy

Medical Oncology Updates in Pancreas Cancer

2023 Johns Hopkins Updates in Gastrointestinal Cancers

T. Bekaii-Saab